MoonLake Immunotherapeutics downgraded by Wolfe Research
$MLTX
Biotechnology: Pharmaceutical Preparations
Health Care
Wolfe Research downgraded MoonLake Immunotherapeutics from Outperform to Peer Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/19/2025 | $61.00 | Peer Perform → Outperform | Wolfe Research |
| 3/18/2025 | $67.00 | Outperform | RBC Capital Mkts |
| 1/17/2025 | $62.00 → $82.00 | Neutral → Buy | Goldman |
| 11/5/2024 | $92.00 → $73.00 | Outperform | Wedbush |
| 8/26/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/25/2024 | $104.00 | Outperform | Oppenheimer |
| 4/2/2024 | $62.00 | Neutral | Goldman |
| 2/15/2024 | $77.00 | Outperform | Wolfe Research |